secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2023-03-15T23:59:59+00:00
Accession:  0001193125-23-071350
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC
--------------------------------------------------------------------------------

- Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.
- Cash, equivalents and marketable securities $661.0M as of Dec 31, 2022; no debt disclosed.
- R&D expense Q4 2022 $16.9M (down from $22.0M); G&A $7.4M (vs $7.6M) YoY.
- Dosed first patient in Phase 1b combo study of NUV-868 with olaparib or enzalutamide; Phase 1 monotherapy ongoing.
- Nominated first DDC clinical candidate; expects IND submission by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/0001193125-23-071350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/d481540d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-071350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer